Therefore, Rac1 can be suggested as a potential therapeutic target for inhibiting EMT process, and new treatment strategy to inhibit postoperative recurrence in HCC patients with vascular invasion or advanced tumor stage. This evidence concerns the gene RAC1 and hepatocellular carcinoma.